How Successful Is Wegovy for Weight Loss — and What Does the Evidence Actually Show?

What do the clinical trials say about how successful Wegovy actually is?

The headline number from the pivotal STEP 1 trial is 15% average weight reduction over 68 weeks. That translates to about 15.3 kg lost, compared with 2.6 kg in the placebo group. Around 70% of participants lost at least 10% of their starting weight, and roughly a third lost 20% or more. These are not cherry-picked results from a small sample; the trial enrolled 1,961 adults across multiple countries, all without type 2 diabetes.

The STEP programme overall (covering adults with diabetes, cardiovascular disease and other conditions) consistently showed meaningful losses, though the degree varied with health status. People with type 2 diabetes tended to lose less than those without it, which is one reason Wegovy and Ozempic are separate products with separate licences.

The higher 7.2mg dose tells an even more striking story. The MHRA approved it in January 2026, and the dedicated single-dose pen followed in April 2026 for adults with a BMI of 30 or above. Trials at this dose reported around 20.7% average weight loss over 72 weeks, approaching results seen with tirzepatide at its highest dose. You can read more about the full Wegovy success rate by dose to understand how the numbers shift across the titration schedule.

One thing the trials are clear about: stopping treatment tends to reverse most of the loss within a year. Wegovy works while you take it, within an active lifestyle programme. It is not a short-term fix.

Which adults are most likely to see the best results on Wegovy?

Semaglutide's licence covers adults with a BMI of 30 or above, or 27 to 29.9 alongside at least one qualifying condition, high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, or type 2 diabetes among them. That is the legal starting point, verified by NHS guidance on semaglutide. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance, typically 2.5 kg/m² below those headline figures.

Within that eligible group, trial evidence points to a few factors that influence outcomes. People who reach the full maintenance dose and stay on it consistently tend to lose more. Those who engage with the lifestyle element (not a crash diet, but a sustainable calorie reduction alongside enough protein and regular movement) do better than those treating the injection as the only intervention.

Early response also matters. NICE guidance on semaglutide (TA875) suggests reviewing whether to continue if less than 5% weight loss is achieved after six months at the maintenance dose. That is a clinical conversation, not a reason to panic if progress feels slow in the first few weeks while the body adjusts to each titration step.

Pregnancy, breastfeeding, and actively trying to conceive are situations where Wegovy is not recommended. The medicine is not licensed for under-18s. A prescriber will go through your full medical history before a prescription is issued.

How to be successful on Wegovy: what actually makes the difference?

A question our prescribers hear regularly is whether the injection does all the work. The honest answer is no, and knowing that from the start makes outcomes better, not worse. Wegovy reduces appetite significantly, which makes eating less feel far more manageable than it would through willpower alone. But the programme it sits inside still requires a few concrete habits.

Consistency with the injection day matters more than people expect. Missing doses or forgetting to keep the pen in the fridge (tucking it in the door next to the milk is a routine that works for many people) disrupts the steady-state concentration that drives appetite suppression. If you want practical, evidence-informed tips for getting the most out of Wegovy, the detail is worth reading before you start.

Protein intake deserves attention. Rapid weight loss on any GLP-1 medicine carries some risk of losing muscle alongside fat, particularly without adequate protein and some resistance activity. Staying well hydrated helps manage the gastrointestinal side effects (nausea, loose stools, and reflux are common in the early weeks) and those side effects settle for most people as the dose stabilises. If they don't, that is a conversation for your prescriber, not something to push through alone.

For a broader look at what success on Wegovy looks like across different starting points, including people who have transferred from other treatments, the picture is more varied and more encouraging than the trial averages alone suggest. If you would like to see how this plays out in practice, you can read a real Wegovy success story from someone who went through the full treatment journey.

Is Wegovy available privately, and what does clinical oversight involve?

On the NHS, Wegovy is available through specialist weight management services under NICE TA875, but waiting lists are long and the criteria are specific. Many people who qualify for treatment under the licence do not meet the narrower NHS thresholds, or simply cannot wait. Private prescribing through a regulated online pharmacy is the alternative, and the clinical oversight involved is not optional or cursory, it is a legal requirement for a prescription medicine.

At nume, every consultation is read by a GPhC-registered Independent Prescriber on the day it is submitted. Identity is verified, current weight is confirmed on video, and medical history is reviewed in full before any prescription is issued. There are no auto-renewals; every repeat order goes through the same clinical re-review. If you want to understand how Wegovy works and what the full treatment journey involves, that page covers the mechanism, the titration schedule, and what to expect at each stage.

Cost is a real consideration. The private cost of Wegovy in the UK varies significantly by dose and provider; what matters is that any legitimate price includes a clinical assessment and a genuine prescription, not just a pen dispatched without one. A word on that: the MHRA has documented counterfeit weight-loss pens seized from online sellers operating without a prescription. Verify any pharmacy you use on the GPhC register before purchasing.

If you are ready to find out whether you are clinically suitable, start your free consultation and a prescriber will review your case the same day.